Cargando…

A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?

BACKGROUND: Our previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia patients compared with healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting schizophrenia was suggested. METHODS: ACE activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nani, João V, Dal Mas, Caroline, Yonamine, Camila M, Ota, Vanessa K, Noto, Cristiano, Belangero, Sintia I, Mari, Jair J, Bressan, Rodrigo, Cordeiro, Quirino, Gadelha, Ary, Hayashi, Mirian A F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Regular Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745254/ https://www.ncbi.nlm.nih.gov/pubmed/32696960 http://dx.doi.org/10.1093/ijnp/pyaa050

Ejemplares similares

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015)

Schneider’s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis
por: Malinowski, Fernando R., et al.
Publicado: (2019)

T97. CANNABIS USE IMPACTS SYMPTOM PRESENTATION IN ANTIPSYCHOTIC NAIVE PATIENTS IN FIRST EPISODE OF PSYCHOSIS (FEP)
por: Coutinho, Luccas, et al.
Publicado: (2018)

Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
por: Santoro, Marcos Leite, et al.
Publicado: (2018)

Hair cortisol in drug-naïve first-episode individuals with psychosis
por: Andrade, Elvis H., et al.
Publicado: (2016)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data
por: Gouvêa, Eduardo S., et al.
Publicado: (2017)

S128. CORRELATION OF DURATION OF UNTREATED PSYCHOSIS WITH TREATMENT RESPONSE ON THE SYMPTOM DIMENSIONS OF SCHIZOPHRENIA
por: Elias, Beatriz Yukie, et al.
Publicado: (2018)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages
por: Ota, Vanessa Kiyomi, et al.
Publicado: (2019)

Evaluation of NDEL1 oligopeptidase activity in blood and brain in an animal model of schizophrenia: effects of psychostimulants and antipsychotics
por: Nani, João V., et al.
Publicado: (2020)

Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis
por: Gouvea, E S, et al.
Publicado: (2016)

T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Assunção-Leme, Idaiane, et al.
Publicado: (2018)

Linkage Replication for Chromosomal Region 13q32 in Schizophrenia: Evidence from a Brazilian Pilot Study on Early Onset Schizophrenia Families
por: Gadelha, Ary, et al.
Publicado: (2012)

Evaluation of the efficacy of transcranial direct current stimulation in the treatment of cognitive symptomatology in the early stages of psychosis: study protocol for a double-blind randomized controlled trial
por: Rabanea-Souza, Thais, et al.
Publicado: (2019)

S174. POLYENVIRONMENTAL AND POLYGENIC RISK SCORES AND THE EMERGENCE OF PSYCHOTIC EXPERIENCES IN CHILDREN AND ADOLESCENTS
por: Belangero, Sintia, et al.
Publicado: (2020)

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia
por: Pinaya, Walter H. L., et al.
Publicado: (2016)

Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
Publicado: (2023)

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder
por: de Jong, Simone, et al.
Publicado: (2018)

T100. NICOTINE USE IMPACTS NEGATIVE SYMPTOMS SEVERITY IN SCHIZOPHRENIA
por: Oliveira, Hianna, et al.
Publicado: (2018)

Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls
por: Matsuzaka, Camila T., et al.
Publicado: (2017)

PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia
por: Ota, Vanessa K., et al.
Publicado: (2014)

Diversity matters: opportunities in the study of the genetics of psychotic disorders in low- and middle-income countries in Latin America
por: Fonseca, Lais, et al.
Publicado: (2020)

How challenging is to manage agitated patients?
por: Cavalcante, Daniel A., et al.
Publicado: (2019)

Association between Insertion-Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and Treatment Response to Antipsychotic Medications: A Study of Antipsychotic-Naïve First-Episode Psychosis Patients and Nonadherent Chronic Psychosis Patients
por: Nadalin, Sergej, et al.
Publicado: (2022)

T117. INVESTIGATION OF FORMAL THOUGHT DISORDER AND RESPONSE TO TREATMENT IN SCHIZOPHRENIA
por: Loures Malinowski, Fernando Rocha, et al.
Publicado: (2018)

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone
por: Gómez-Revuelta, Marcos, et al.
Publicado: (2020)

Antipsychotic prescribing choices in patients with First Episode Psychosis
por: Fallon, J., et al.
Publicado: (2022)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Liu-Seifert, Hong, et al.
Publicado: (2009)

The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice
por: May, Meghan, et al.
Publicado: (2019)

Risperidone: Acute psychosis secondary to stroke: case report
Publicado: (2020)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Designed proteinoid polymers and nanoparticles encapsulating risperidone for enhanced antipsychotic activity
por: Lugasi, L., et al.
Publicado: (2020)

Proteinoid Nanocapsules as Drug Delivery System for Improving Antipsychotic Activity of Risperidone
por: Lugasi, Liroy, et al.
Publicado: (2020)

S129. DOES TREATMENT RESISTANT SCHIZOPHRENIA PRESENT A CHARACTERISTIC SYMPTOMATIC SIGNATURE?
por: Bertolucci, Bruno, et al.
Publicado: (2018)

Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia
por: Koga, Gabriela, et al.
Publicado: (2022)

Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment
por: McGorry, Patrick D., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6rkp8b6mtj7s1hqvq2br58g0mg